Stefan Schreiber (S Schreiber)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

International journal of colorectal disease

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Ian L P Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin Biroulet
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary pharmacology & therapeutics (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Stefan Schreiber, Georg H Waetzig, Matthias Laudes, Philip C Rosenstiel
Cardiovascular safety of vitamin B 3 administration. Nature medicine (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, Daniela Pohlschneider, Eugen Urzica, Petra Hartmann, Jennifer Zemke, Ulrich Tappe, Stefan Schreiber, Nadine Steinkat, Jana Langbrandtner, Angelika Hüppe, Tom Stargardt
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD BIO-ASSIST study). Alimentary pharmacology & therapeutics 59 (9) (2024)
Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V Loftus, Ian L P Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin Biroulet
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Alimentary pharmacology & therapeutics 60 (5) (2024)
Stefan Schreiber, Raymond K Cross, Remo Panaccione, Geert D'Haens, Peter Bossuyt, Iris Dotan, Jean Frederic Colombel, Edouard Louis, Marla C Dubinsky, Kristina Kligys, Ezequiel Neimark, Alexandra Song, Javier Zambrano, Jasmina Kalabic, Erica Cheng, Yafei Zhang, Marc Ferrante
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary pharmacology & therapeutics (2024)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Ulf Helwig, Niels Teich, Carsten Schmidt, Petra Hartmann, Christina Sobotzki, Stefan Schreiber
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study. Alimentary pharmacology & therapeutics (2023)
Bernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, Philipp Efken, Wolfgang Mohl, Thomas Krause, Martin Hoffstadt, Robert Ehehalt, Leo Trentmann, Axel Schweitzer, Petra Jessen, Petra Hartmann, Stefan Schreiber
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO IBD -study. Alimentary pharmacology & therapeutics (2023)
Lea Henneke, Kristina Schlicht, Nadia A Andreani, Tim Hollstein, Tobias Demetrowitsch, Carina Knappe, Katharina Hartmann, Julia Jensen-Kroll, Nathalie Rohmann, Daniela Pohlschneider, Corinna Geisler, Dominik M Schulte, Ute Settgast, Kathrin Türk, Johannes Zimmermann, Christoph Kaleta, John F Baines, Jane Shearer, Shrushti Shah, Grace Shen-Tu, Karin Schwarz, Andre Franke, Stefan Schreiber, Matthias Laudes
A dietary carbohydrate - gut Parasutterella - human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes. Gut microbes 14 (1) (2022)
Bram Verstockt, Valery Volk, Charlot Jaeckel, Dahham Alsoud, João Sabino, Susanna Nikolaus, Marc Ferrante, Nicole Krönke, Friedrich Feuerhake, Gert De Hertogh, Philip Rosenstiel, Séverine Vermeire, Stefan Schreiber, Marc Ferrante, Konrad Aden
Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Alimentary pharmacology & therapeutics 56 (2) (2022)
Stefan Schreiber, Peter M Irving, Ala I Sharara, Maria Dolores Martin-Arranz, Xavier Hébuterne, Plamen Penchev, Silvio Danese, Prodromos Anthopoulos, Gamar Akhundova-Unadkat, Filip Baert
Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Alimentary pharmacology & therapeutics 55 (6) (2022)
Arunabh Sharma, Silke Szymczak, Malte Christoph Rühlemann, Sandra Freitag-Wolf, Carolin Knecht, Janna Enderle, Stefan Schreiber, Andre Franke, Wolfgang Lieb, Michael Krawczak, Astrid Dempfle
Linkage analysis identifies novel genetic modifiers of microbiome traits in families with inflammatory bowel disease. Gut microbes 14 (1) (2022)
Stefan Schreiber, Katsuhiko Yamamoto, Rafael Muniz, Takafumi Iwura
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Pharmacology research & perspectives 8 (3) (2021)
Tina Schreiber, Maren Falk-Paulsen, Jan Kuiper, Konrad Aden, Rainer Noth, Nicolas Gisch, Stefan Schreiber, Philip Rosenstiel, Burkhard Bewig
IL23R on myeloid cells is involved in murine pulmonary granuloma formation. Experimental lung research 47 (7) (2021)
HoUng Kim, Rieke E Alten, J R Fraser Cummings, Silvio Danese, Geert R A M D'Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, Jong Hyuk Lee, James O Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven R A Simoens, René Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13 (1) (2021)
Susanna Nikolaus, Georg H Waetzig, Sven Butzin, Monika Ziolkiewicz, Natalie Al-Massad, Florian Thieme, Ulf Lövgren, Birgitte B Rasmussen, Torsten M Reinheimer, Dirk Seegert, Philip Rosenstiel, Silke Szymczak, Stefan Schreiber
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases. International journal of colorectal disease 33 (7) (2018)
F Bär, T Kühbacher, N A Dietrich, T Krause, Andreas Stallmach, N Teich, Stefan Schreiber, Jens Walldorf, R Schmelz, C Büning, K Fellermann, J Büning, U Helwig, null null
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Alimentary pharmacology & therapeutics 47 (5) (2017)